Diabetic Macular Edema (DME) Market to reach USD 3.93 billion by 2029, Business opportunities

Diabetes macular edema (DME) is one of the most common causes of diabetic visual loss. It's thought to be caused by the retinal vasculature's hyper-permeability. Diabetic retinopathy severity is associated to macular edema. The pathophysiology and molecular processes involved in the development of diabetic macular edema are complex, necessitating a better knowledge of the disease's pathogenesis and molecular pathways. In recent years, pharmaceutical companies have targeted combinations of many medicines to treat DME, aiming to target separate routes or different phases of the same pathway. Medication and laser surgery are two well-established treatments to preserve the patient's vision and decrease future vision loss.

View Detailed Report: https://www.databridgemarketresearch.com/reports/global-diabetic-macular-edema-market

Data Bridge Market Research analyses that the diabetic macular edema (DME) market was valued at USD 3.02 billion in 2021 and is expected to reach USD 3.93 billion by 2029, registering a CAGR of 3.36% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

In recent years, the diabetic macular edema (DME) market is anticipated to grow rapidly during the forecast period. Diabetic macular edema (DME) is characterized by fluid accumulation in the macula, which is the region of the retina important for vision. Edema can result from the leakage of plasma contents into the surrounding area, causing the accumulation. Diabetic macular edema is one of the primary causes of blindness in diabetic patients, affecting around 12% of type 1 diabetes patients and 28% of type 2 diabetic patients in developing nations in 2011. Controlling blood sugar levels, or glycaemia, lipid levels, and renal function is the conventional treatment for diabetic macular edema. The Diabetes Control and Complications Trial (DCCT) found that individuals who received aggressive glycaemic treatment had a 2.3 percent lower risk of DME.

Diabetic Macular Edema (DME) Market Dynamics

Opportunities

Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for market growth in diabetic macular edema (DME). Along with this, rising approvals and launches of new diabetic macular edema (DME) drugs will further propel the market's growth rate.

Drivers

Increasing prevalence of diabetes

The rising prevalence of diabetes is anticipated to influence the diabetic macular edema (DME) market's growth during the forecast period. The prevalence rate of diabetic macular edema (DME) in type 2 diabetes patients is higher than in type 1 diabetes patients. Along with this, the growing incidences of hyperlipidaemia, fluid retention, hypertension and kidney diseases are the various medical ailments developing the risk of diabetic macular edema (DME).

Some of the major players operating in the diabetic macular edema (DME) market are:

LEO Pharma A/S (Denmark)

Amneal Pharmaceuticals LLC. (US)

Glenmark Pharmaceuticals Limited (India)

Dr. Reddy's Laboratories Ltd. (India)

AstraZeneca (UK)

Johnson & Johnson Private Limited (US)

Bausch Health Companies Inc. (Canada)

Eli Lilly and Company (US)

AbbVie Inc. (US)

Abbott (US)

F. Hoffmann-La Roche Ltd. (Switzerland)

Type

Focal Diabetic Macular Edema (DME)

Diffuse Diabetic Macular Edema (DME)

Treatment

Laser Therapy

Anti-VEGF Agents

Steroids

Surgical

Others

North America dominates the diabetic macular edema (DME) market because of the growing prevalence of diabetes and presence of refined healthcare expenditure in this region. Additionally, presence sophisticated photocoagulation laser manufacturers which is projected to propel the market's growth rate in this region.

Europe is expected to grow during the forecast period due to increasing cases of diabetic macular edema (DME) and rising healthcare expenditure in this region. Also, growing focus of major key players on novel technology is estimated to escalate the market's growth rate in this region.

Explore More Reports:

https://databridgemarketresearchreports.blogspot.com/2024/06/nasal-spray-market-to-reach-value-of.html

https://databridgemarketresearchreports.blogspot.com/2024/06/medical-radiation-detection-monitoring_24.html

https://databridgemarketresearchreports.blogspot.com/2024/06/refurbished-medical-device-market-will_24.html

https://databridgemarketresearchreports.blogspot.com/2024/06/medical-gloves-market-to-undergo-cagr.html

About Data Bridge Market Research:

An absolute way to predict what the future holds is to understand the current trend! Data Bridge Market Research presented itself as an unconventional and neoteric market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are committed to uncovering the best market opportunities and nurturing effective information for your business to thrive in the marketplace. Data Bridge strives to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process. Data Bridge is a set of pure wisdom and experience that was formulated and framed in 2015 in Pune.

Data Bridge Market Research has more than 500 analysts working in different industries. We have served more than 40% of the Fortune 500 companies globally and have a network of more than 5,000 clients worldwide. Data Bridge is an expert in creating satisfied customers who trust our services and trust our hard work with certainty. We are pleased with our glorious 99.9% customer satisfaction rating.

Contact Us: -
Data Bridge Market Research
US: +1 614 591 3140
United Kingdom: +44 845 154 9652
APAC: +653 1251 975
Email: - sopan.gedam@databridgemarketresearch.com

This release was published on openPR.